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ABSTRACT: Implantable devices are versatile and promising drug
delivery systems, and their advantages are well established. Of these
advantages, long-acting drug delivery is perhaps the most valuable.
Hydrophilic compounds are particularly difficult to deliver for
prolonged times. This work investigates the use of poly(caprolactone)
(PCL)-based implant coatings as a novel strategy to prolong the
delivery of hydrophilic compounds from implantable devices that have
been prepared by additive manufacturing (AM). Hollow implants were
prepared from poly(lactic acid) (PLA) and poly(vinyl alcohol) (PVA)
using fused filament fabrication (FFF) AM and subsequently coated in
a PCL-based coating. Coatings were prepared by solution-casting
mixtures of differing molecular weights of PCL and poly(ethylene
glycol) (PEG). Increasing the proportion of low-molecular-weight
PCL up to 60% in the formulations decreased the crystallinity by over
20%, melting temperature by over 4 °C, and water contact angle by over 40°, resulting in an increased degradation rate when
compared to pure high-molecular-weight PCL. Addition of 30% PEG to the formulation increased the porosity of the formulation by
over 50% when compared to an equivalent PCL-only formulation. These implants demonstrated in vitro release rates for hydrophilic
model compounds (methylene blue and ibuprofen sodium) ranging from 0.01 to 34.09 mg/day, depending on the drug used. The
versatility of the devices produced in this work and the range of release rates achievable show great potential. Implants could be
specifically developed in order to match the specific release rate required for a number of drugs for a wide range of conditions.
KEYWORDS: poly(caprolactone) coatings, poly(ethylene glycol), implantable drug delivery, hydrophilic drugs, additive manufacturing,
3D printing, fused filament fabrication
1. INTRODUCTION
Implantable drug delivery devices offer many advantages
including improved patient compliance and reduced side
effects, among others.1−4 These are achieved by maintaining a
therapeutic concentration over a prolonged time frame,
without the need for frequent tablets or injections.5 They
can be used for a wide variety of clinical applications including
women’s health, oncology, ocular disease, pain management,
infectious disease, and central nervous system disorders.3,6 The
majority of implant devices are polymeric rods designed to be
inserted subcutaneously or intramuscularly, and the most
common method of insertion is via a needle or by surgical
implantation.7,8 This can be relatively traumatic for the patient
in comparison to oral drug delivery. However, the long-term
drug delivery and improvements in patient compliance that
this route of delivery offers may outweigh this disadvantage.
This could be particularly important in chronic conditions
where poor patient compliance is a challenge, for example in
human immunodeficiency virus (HIV) or mental health
conditions.
Many implants are made of non-biodegradable materials,
such as silicone (e.g., Norplant9) or poly(ethylene-vinyl
acetate) (e.g., Nexplanon10 and Ocusert11) and, therefore,
need to be removed from the body once they have achieved
their purpose. This removal can often be distressing for the
patient and may be more invasive than the insertion of the
device.12 Development of a device made entirely from
biodegradable polymers could circumvent this issue, as the
device would biodegrade naturally to form products that can
be excreted easily by the body once the device has achieved its
effect,5 although still offering the possibility of early removal if
adverse effects necessitated it.13 Commonly used biodegrad-
able (or soluble), biocompatible, and U.S. Food and Drug
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Administration (FDA)-approved polymers include poly(lactic
acid) (PLA), poly(vinyl alcohol) (PVA), and poly(capro-
lactone) (PCL).5,14−16 These polymers have been widely used
for biomedical applications including cardiovascular stents15
and implants.5,14,16,17
Hot-melt extrusion (HME), solution casting, injection
molding, and additive manufacturing (AM) (also known as
3D printing) are common methods for the manufacture of
implants5 and commonly produce devices in which the drug is
dispersed throughout (matrix-type implants). This has some
drawbacks and limits the number of drugs which are suitable
due to the high temperatures or solvents used.5 In comparison,
reservoir-type devices may be fabricated and drug loaded
separately, thus limiting drug exposure to adverse conditions.
The aim of this study is to use AM, specifically fused filament
fabrication (FFF), to produce a reservoir-type implantable
device. In this way, the device is manufactured separately from
the drug compound and, therefore, limits the drug exposure to
high temperatures or solvents. This technology has already
been investigated for the manufacture of oral dosage forms,
implants, and protheses.18,19 The sustained delivery of
hydrophilic drugs is a particular challenge, and numerous
strategies to prolong their release have been investigated
including colloidal systems, nanoparticles, gold nanoclusters,
and liposomes.20−22 In order to prolong the release from the
implants produced in this work, they will subsequently be
coated in a polymeric film, which will control the drug release
from the device.
Hollow implantable devices, made from biocompatible
polymers (PLA and PVA), were prepared using FFF AM.
Subsequently, these devices were coated with polymeric films
made from PCL and poly(ethylene glycol) (PEG). The
polymeric films and the resulting devices were characterized
using a range of techniques including X-ray micro-computer
tomography (μ-CT), attenuated total reflectance−Fourier
transform infrared (ATR-FTIR), X-ray diffraction (XRD),
contact angle goniometry (CAG), and differential scanning
calorimetry (DSC). Drug release from the designed devices
was characterized by delivering hydrophilic model compounds
(methylene blue (MB) and ibuprofen sodium (IBU sodium))
using an in vitro release model.
2. MATERIALS AND METHODS
2.1. Materials. Granulated PLA (Ingeo Biopolymer
4043D) was purchased from NatureWorks (Minnetonka,
MN, USA). Filament PVA was purchased from Ultimaker
(Geldermalsen, The Netherlands). PCL 6506 (MW = 50 000
Da, i.e., high molecular weight), henceforth referred to as H-
PCL, and PCL 2054 (MW = 550 Da, i.e., low molecular
weight), henceforth referred to as L-PCL, were provided by
Perstorp (Malmö, Sweden). MB, IBU sodium, PEG (MW =
1000 Da), and phosphate-buffered saline (PBS) tablets (pH
7.4) were purchased from Sigma-Aldrich (Dorset, UK).
Dichloromethane (DCM) was obtained from Merck (Darm-
stadt, Germany).
2.2. Methods. 2.2.1. Implant Design and Manufacture.
Single-screw HME was used to produce the PLA filament for
the implant manufacture in combination with the PVA
filament. As described previously by Stewart et al.,23 PLA
pellets were added to a filament extruder (3Deveo, Utretch,
The Netherlands) at an extrusion speed of 5 rpm and a
filament fan speed of 70%. The temperature was controlled
between 170 and 190 °C.
A hollow implant was designed (Figure 1A) using computer-
aided design (CAD) software and printed using an Ultimaker 3
AM system (Ultimaker, Geldermalsen, The Netherlands) using
Cura software. The Ultimaker 3 system was equipped with 0.4
mm extruder nozzles loaded with PLA and PVA filament,
respectively. The print speed was 70 mm/s, the print
Figure 1. (A) CAD design used to produce the AM implant. (B) (1) Uncoated implant, (2) cross-sectional view of an uncoated implant, and (3)
cross-sectional view of a coated implant.
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temperature used was 205 °C, the build plate temperature was
85 °C, and the layer height used was 0.1 mm. After the AM
process, implants were loaded manually with solid drug
powder core (either MB (68.6 ± 5.1 mg) or IBU sodium
(68.1 ± 3.0 mg)). Subsequently, the implants were coated by
solution casting13 with a biodegradable PCL or PCL/PEG film
to control the drug release from the implant (Figure 1B). The
thickness of each of the implant coatings was analyzed using a
digital calliper and the PCL solution concentration altered, if
necessary, to produce coatings with the same thickness.
2.2.2. PCL Film Formulation. Films of varying proportions
of H-PCL, L-PCL, and PEG 1000 were prepared by solution
casting.13 The appropriate ratios of constituents (1.5 g) (Table
1) were dissolved in 10 mL of DCM, 5 g of the resulting
solution was poured into a glass Petri dish, and the DCM was
allowed to evaporate at room temperature (20 °C) to form
films.13
2.2.3. PCL Film Characterization. ATR-FTIR spectrometry
was used to investigate any chemical interactions between the
materials within each of the films. An Accutrac FT/IR-4100
series (Jasco, Essex, UK) equipped with MIRacle diamond
ATR was used at room temperature (20 °C). The IR
transmission spectra were recorded between 600 and 4000
cm−1 with a resolution of 4.0 cm−1. An average of 64 repeat
scans were taken to obtain each spectrum.
The thermal properties of the PCL films were investigated
using DSC. Analysis was carried out on samples of each
formulation on a DSC Q100 differential scanning calorimeter
(TA Instruments, New Castle, DE, USA). Samples of each film
were heated from 0 to 100 °C at a rate of 10 °C/min. The
melting temperature was determined from the peak of the DSC
endotherm.
The crystalline structure of the films was evaluated by XRD
analysis. XRD spectra were recorded at room temperature
using a D5000 diffractometer (Siemens, Munich, Germany)
with a Kristalloflex 710 generator with filtered Cu Kα radiation
(λ = 1.5405 Å; 40 kV; 30 mA). Data were collected in the 2θ
range from 10° to 70° with a step of 0.02° and counting time
of 1 s/step. The crystallinity of each of the films was calculated
using eq 1 after deconvoluting the peaks present in the
diffractograms.
=
+
X
I
I Ic
c
c a (1)
where Ic represents the area under crystalline peaks and Ia
represents the area under amorphous halos.24
Degradation of each of the PCL films was investigated. The
initial dry weights (W0) of three replicates (1.0 cm × 2.5 cm
and 89.58 (±23.00) μm thick) of each film were recorded. The
films were then placed in 5 mL of PBS (pH 7.4) at 37 °C with
shaking at 40 rpm. The films were removed at defined time
points, excess water was removed, and the weights at time t
were recorded (Wt). The films were then placed in 5 mL of
fresh PBS (pH 7.4) at 37 °C.
The percentage weight remaining was calculated using eq 2:
= ×W
W
% wt remaining 100t
0 (2)
The contact angle of deionized water with the surface of
each the films was measured using the sessile drop method. For
this purpose, an Attension Theta tensiometer (Biolin Scientific,
Gothenburg, Sweden) was used, and OneAttension software
was used to analyze the results.25 Each reported contact angle
is a mean of three measurements taken from random areas on
each film formulation. The volume of each droplet used was
kept constant (4 μL), and each contact angle reported was
measured 1.94 s after release of the droplet.
In addition, the porosity of each of the films was also
evaluated in terms of mercury intrusion porosimetry (MIP).
All tests were carried out on an Autopore IV 9500 instrument
(Micromeritics, Norcross, GA, USA). Prior to analysis, all
samples were dried at 40 °C and placed into a penetrometer to
ensure the correct mercury fill into the voids. The relationship
between applied pressure and pore size is defined by the
Washburn equation, which assumes a relationship between the
applied pressure and pore diameter using physical properties of
a non-wetting material (in this case, mercury which has a
contact angle of 141° with the test materials). The applied
pressure ranged from 1 to 60 000 psi.
Finally, a TCS SP8 laser scanning confocal microscope
(Leica, Wetzlar, Germany) was used to acquire sequential
images of a H35L35P30 film containing a hydrophobic dye
(Nile red) and a hydrophilic dye (fluorescein). Excitation at
488 and 552 nm was achieved using a laser, and photons were
collected via HyD Leica spectral detectors.
2.2.4. Implant Characterization. Optical coherence tomog-
raphy (OCT) using an EX1301 OCT microscope (Michelson
Diagnostics, Kent, UK) enabled visualization of implant
coatings and the drug within the implant cavity. Additionally,
X-ray μ-CT scans were performed on the implants following
the same methodology reported by Matthew and Domińguez-
Robles et al.26,27 Briefly, the 3D reconstruction volumes and
inner structures of the implants were observed by using a
Skyscan 1275 system (Bruker, Billerica, MA, USA) with a
Hamamatsu L11871 source. The microfocus of the X-ray
source of the μ-CT scanner had maximum voltage of 40 kV
and maximum current of 250 μA. Samples were mounted
vertically on dental wax and positioned 59.791 mm from the
source, and the camera-to-source distance was 286 mm. No
filter was applied for an exposure time of 49 ms. The images
generated were 1944 × 1413 pixels with a resolution of 17 μm
per pixel. The data were then collected, and Data Viewer and
CT-An software were used to analyze them. Finally, CTvol
software was applied to generate 3D reconstruction images.
2.2.5. In Vitro Release. Implants were loaded with MB or
IBU sodium, placed in 500 mL of PBS (pH 7.4) at 37 °C, and
shaken at 40 rpm. Samples (0.5 mL) of the release medium
were taken at specified time points and replaced with equal
Table 1. Composition of Polymeric Films Prepared by
Solution Casting
composition (%)
formulation H-PCL L-PCL PEG 1000
H100 100 0 0
H70L30 70 30 0
H50L50 50 50 0
H40L60 40 60 0
H45L45P10 45 45 10
H40L40P20 40 40 20
H35L35P30 35 35 30
H30L30P40 30 30 40
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volumes of PBS (pH 7.4).28 MB and IBU sodium were
quantified using UV spectroscopy and RP-HPLC, respectively,
as previously described by Stewart et al.23 Total drug release at
each time point was calculated using eq 3, taking into account
sample that had been removed previously to offset any dilution
from sample removal and replacement with fresh medium.
= + ×W W
W
% drug release 100t s
0 (3)
where Wt is the weight of drug released at time t, Ws is the
weight of drug removed in all previous samples, and W0 is the
weight of drug in the implant at t = 0.
2.3. Data Analysis. 2.3.1. Similarity and Difference
Factor. Release profiles from each of the implants were
compared by calculating and comparing the difference (F1)
and similarity (F2) factors. F1 was calculated using eq 4 and
measures the percentage difference between two curves at each
time point; it is a measurement of the relative error between
the two curves.
∑ ∑= {[ − ] [ ]} ×
= =
F R T R( ) / 100
t
n
t t
t
n
t1
1 1 (4)
where n is the number of time points, Rt is the reference
dissolution value at time t, and Tt is the test dissolution value at
time t.29,30
F2 is calculating using eq 5 and is a logarithmic trans-
formation of the sum-squared error of differences between the
test and reference products over all time points, n.
∑= {[ − ] × }
=
−F n R T50 log (1/ ) ( ) 100
t
n
t t2
1
0.5
(5)
In order for two dissolution profiles to be considered similar,
the F1 value should be lower than 15 (0−15) and the F2 value
should be more than 50 (50−100).29,30 The mean profiles are
assumed to differ by no more than 15% if F2 is between 50 and
100.31
2.3.2. Statistical Analysis. Where appropriate all data was
expressed as a mean ± standard deviation (SD) and compared
using one-way analysis of variance (ANOVA) with Tukey’s
HSD post hoc analysis. Moreover, Kruskal−Wallis test followed
by Dunn post hoc analysis was used to compare drug release
rates from implants coated with different formulations. In all
cases, p < 0.05 was the minimum value considered acceptable
for rejection of the null hypothesis.
3. RESULTS AND DISCUSSION
3.1. Implant Design and Manufacture. PLA and PVA
are widely used materials in AM, and as such the conditions
have been previously optimized.23,32 Moreover, these polymers
have been approved by the FDA for pharmaceutical and
medical applications, and they have been extensively used for
drug delivery applications.33−35 Implant dimensions of 2.5 ×
40.0 mm were chosen because this shape and size have already
been shown to be acceptable in commercially available
products (e.g., Nexplanon) and applicator devices have already
been developed for an implant of these dimensions.36 These
types of implants have been described before for drug release
purposes.23 However, it was reported that they were not ideal
to sustain the release of drugs for prolonged periods of time.
Accordingly, a coating capable of sustaining drug permeation
will be a great improvement. For this purpose, a PCL-based
coating was designed.
3.2. PCL Film Characterization. PCL has been
extensively used for pharmaceutical and medical applica-
tions.5,37−39 PCL was chosen as the basis of the polymeric film
because it is biodegradable, biocompatible, and low cost.12,40
The main applications of this type of polymer have been the
preparation of nanoparticles for drug delivery or its use as
scaffold for tissue regeneration.37,38 PCL has previously been
used as a rate-controlling membrane.13 However, we propose a
novel approach where the properties of the membrane,
including its drug permeation, will be tailored by adjusting
the coating composition. To the best of our knowledge this
type of coating formulation for sustained drug delivery has not
been reported before.
Before coating implants, different PCL formulations were
prepared and characterized (Table 1). FTIR was used to
analyze the resulting formulations (Figure 2). Typical PCL
absorption bands at ∼1295 cm−1 (C−O and C−C stretching),
∼1730 cm−1 (CO), and ∼2940 and ∼2860 cm−1 (C−H)
are present in all formulations containing PCL41,42 (Figure 2).
The spectra of each of the blends showed the characteristic
peaks of the constituent polymers. Absorption bands at 1725
and 1100 cm−1 are present and have been previously reported
to be associated with the formation of blends between PCL
and PEG.39 Broad bands at 2945 cm−1 (associated with C−H
vibrations in PCL) and 2868 cm−1 (attributed to C−H
stretching within PEG) are evidence of an association between
the functional groups of the constituent polymers.39 Peaks of
all pure materials are present in each formulation, but no new
peaks are formed, indicating that no covalent interactions have
occurred between the compounds and confirming the
formation of a polymer blend rather than a copolymer.
DSC was performed on each of the films to ensure that they
all formed miscible blends that demonstrated a single melting
point (Figure 3). Neither L-PCL nor PEG 1000 showed a
separate melting point at 18−23 °C43 and 37−40 °C,44,45
respectively. This reinforces the results from FTIR, which
suggests there are no covalent interactions occurring between
PCL and PEG 1000. It has been previously shown that PCL−
PEG mixtures show discrete melting points for both PCL and
PEG.46 However, these studies used different molecular
Figure 2. ATR-FTIR spectra of each of the polymeric film
formulations.
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weights of PEG, suggesting that molecular weight has an effect
on the miscibility of the compounds. It is observed that
addition of L-PCL, which is liquid at room temperature (20
°C), has the effect of lowering the melting temperature of
H100, and that as the proportion of L-PCL is increased, the
melting point is further reduced. From Figure 3B1-2, it is
observed that addition of PEG 1000 to the films does not
further reduce the melting point of the membranes. It has been
reported that an increase in the degree of crystallinity of PCL is
observed with the addition of PEG as a result of the
plasticizing effect of PEG.47,48 It could be that the mobile
PEG chains improve molecular chain mobility, thus accelerat-
ing crystallization rate and acting as sites for PCL crystal
growth, as has been previously reported for PLA.48
Figure S1A (see Supporting Information) shows DSC
thermograms for H-PCL and PEG 1000 mixtures. These
thermograms show that when PEG 1000 is added to H-PCL,
the melting point of PCL decreases as observed previously.
Interestingly, two melting points can be observed clearly for
samples containing 30 and 40% PEG 1000. This was also
observed in samples containing 20%, but this peak is small in
comparison to those seen at higher concentrations. The
melting point can be attributed to the presence of free PEG
1000 chains not mixed with PCL chains. This behavior is not
seen in the films containing L-PCL. PEG 1000 and L-PCL are
miscible. Accordingly, it can be hypothesized that the presence
of L-PCL is required to mix H-PCL and PEG 1000. It is
important to note that this behavior depends on the molecular
weight, as PCL−PEG 600 films did not show two melting
points (Figure S1B, Supporting Information).
XRD was used to evaluate the crystallinity of the samples.
Crystalline peaks for PCL are observed at 21.5°, 22°, and 23.7°
and are attributed to (110), (111), and (200) reflection planes
of the orthorhombic crystal while an amorphous halo is
observed at 20.5°, which corresponds to previously reported
results24,39,41 (Figure 4A,B). These peaks are present in all
formulations, suggesting that the crystalline structure remains
unaltered. In order to calculate the degree of crystallinity, XRD
plots were deconvoluted (Figure 4C) to obtain the area of each
individual peak.
The addition of L-PCL results in a reduction in crystallinity
(Figure 4D). Some samples show a slight deviation from this
trend that can be attributed to the deconvolution and fitting
process. This reduction in crystallinity supports the reduction
in melting temperature observed as the proportion of L-PCL is
increased. Accordingly, it can be concluded that the presence
of L-PCL will reduce the crystallinity of the samples. On the
other hand, an additional crystalline peak appears in the
spectra at 18.5° for H30L30P40 (40% PEG content). This
peak is characteristic of PEG crystalline domains.39 This
explains the increased crystallinity for this formulation,
compared to those with lower PEG 1000 concentration. As
the proportion of PEG 1000 in the films is increased to 40%,
an increase in crystallinity is observed (Figure 4E).
PCL is known to have a long degradation time, up to two
years, but this is dependent on molecular weight.42 As such, a
low-molecular-weight PCL was chosen to be added to H-PCL
to assess the effect on degradation. PCL is also easily miscible
with other polymers and can form copolymers and blends.40,49
Therefore, PEG 1000 was chosen as another component to
assess how it would affect the degradation rate of the films.
Mixtures of L-PCL and PEG 1000 were not tested, as these
have been previously shown to degrade rapidly and are unlikely
to be useful for the pronged release of hydrophilic
Figure 3. Influence of (A) L-PCL and (B) PEG 1000 on (1) DSC endotherm and (2) melting temperature of polymeric films. Exo Up.
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compounds.42 Addition of L-PCL to the formulation increased
the rate of degradation of the films (Figure 5A). This was
expected because the rate of degradation is affected by the
molecular weight of the polymer. Reduced molecular weight
results in a reduced number of ester bonds that need to be
cleaved.50 L-PCL within the formulations is degraded more
quickly than H-PCL; therefore, as the proportion of L-PCL is
increased, the rate of degradation is also increased. In addition,
L-PCL causes a reduction in crystallinity of the formulations
which will contribute to increased degradation. Addition of
PEG 1000 to the formulations (Figure 5B) causes a reduction
in the degradation rate of these films. This is most likely due to
the increased crystallinity that is observed from the addition of
PEG 1000 to the formulation.
Contact angle of water with a material indicates the degree
of hydrophilicity51 and may help to explain any differences in
degradation rate of each of the formulations. A more
hydrophilic material may have a higher the rate of degradation
Figure 4. (A, B) XRD of each film formulation. (C) Deconvoluted XRD pattern of H50L50 showing Gaussian fittings of (110), (111), (200), and
the amorphous halo. The influence of (D) L-PCL and (E) PEG 1000 on the crystallinity of polymeric films.
Figure 5. Influence of (A) L-PCL and (B) PEG 1000 content on the degradation rates of the polymeric films (means ± SD, n = 3).
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as a result of increased water penetration and, therefore,
increased rate of hydrolysis of ester bonds.52,53 However, this
will be dependent on other factors such as crystallinity. The
contact angle found for H100 is lower than results previously
reported (123° 54 and 101° 55) for PCL of a similar molecular
weight, although contact angle is dependent on factors such as
surface properties. For example, a rough surface will result in a
higher contact angle for hydrophobic materials but a lower
contact angle for hydrophilic materials.51,54,55 The addition of
L-PCL has a significant (p < 0.05) effect in reducing the
contact angle of the films (Figure 6A), thereby increasing the
hydrophilicity of the films. Increasing the proportion of L-PCL
above 30% did not have a significant (p > 0.05) effect on
further decreasing the contact angle of the formulations. Jiang
et al.55 reported that the addition of a hydrophilic compound,
hydroxyapatite, resulted in composites with a lower contact
angle than those obtained with pure PCL.
The addition of PEG 1000 causes a significant (p < 0.05)
reduction in contact angle when compared to H50L50 (Figure
6B), but only up to 20% PEG 1000 content (i.e., formulations
H45L45P10 and H40L40P20). For PEG 1000 concentrations
above 30% (i.e., H35L35P30 and H30L30P40), no significant
difference (p > 0.05) in contact angle was observed. Lin et al.56
also reported that increasing the proportion of PEG in
amphiphilic co-networks of poly(dimethylsiloxane) resulted in
a reduction in their contact angle with deionized water up until
a maximum PEG ratio of 6/1. After this point, contact angle
remained constant. Wurth et al.57 reported that inclusion of
oligo-ethylene glycols (OEG) in PCL-OEG-MPO copolymers
resulted in a reduction in contact angle of the resulting
copolymer, but they only tested this effect up to 8%. This effect
could be explained by an interaction between L-PCL and PEG
1000. It is possible that L-PCL and PEG 1000 are interacting
to form hydrophilic domains in which L-PCL is surrounding
PEG 1000. However, as the concentration of PEG 1000
increases above the concentration of L-PCL, there is
insufficient L-PCL to combine with all the PEG 1000, resulting
in the slight increase in contact angle observed. Additionally,
this theory could explain why the expected increase in
degradation rate was not observed with the addition of PEG
1000 and the presence of an additional crystalline peak at 18°
in the XRD studies for formulations containing higher amounts
of PEG 1000.
Characterization results from FTIR, DSC, XRD, degrada-
tion, and contact angle informed which formulations were
investigated further. Four formulations were chosen to be
included in further testing: H50L50, H40L60, and H35L35P30
were included to assess the effect of increasing L-PCL
concentration and addition of PEG 1000, and H100 was
included as a control formulation. The formulations show a
range of degradation times and are, therefore, likely to show a
range of different release profiles in in vitro release models.
Porosity is an important parameter and will have a
significant effect on drug permeation through a polymeric
film (Figure 7).58,59 Before immersion in PBS (pH 7.4), all
membrane formulations showed similar values for porosity.
After immersion in PBS (pH 7.4) for 60 days, all films showed
an increase in porosity (Figure 7A). This increase was
particularly marked for H40L60 and H35L35P30, where the
porosity increased by more than 200% and 300%, respectively,
after immersion in PBS (pH 7.4) for 60 days (Figure 7B).
Figure 7C,D illustrates the log differential intrusion volume
analysis of the selected films before and after immersion in PBS
(pH 7.4). Both H100 and H40L60 profiles (0 days in PBS (pH
7.4)) were homogeneous, and no significant voids were
observed on their surfaces, whereas H50L50 and H35L35P30
exhibited very slight pore size distributions (inset of Figure
7C), below 0.2 mL/g, which can be attributed to the formation
of small surface pits with irregular shapes during the
preparation procedure. After immersion in PBS (pH 7.4) for
60 days, H100, H50L50, and H40L60 showed a monomodal
pore size distribution with a peak value centered around 2−3
μm. However, the addition of PEG 1000 to the polymer blends
in H35L35P30 produced a bimodal shape with an important
increase of the pore size distribution intensity, which indicates
a larger number of pores with smaller pore sizes of 1−2 μm.
After immersion in PBS (pH 7.4), pores are formed in the
polymeric film, as seen in Figure 7E. The addition of PEG in
H35L35P30 allows increased water penetration and formation
of hydrophilic pores.7 Figure 7F shows how the hydrophilic
compound, fluorescein, congregates to form hydrophilic pores
within H35L35P30 and the hydrophobic compound, Nile red,
can be seen throughout the rest of the film. These areas of
PEG 1000 can dissolve more easily to form pores and facilitate
release from these films. It is likely that PEG 1000 domains in
these films dissolve and result in the formation of pores.
3.3. Coated Implant Characterization. Images of coated
implants (H50P50) filled with MB and IBU sodium are shown
in Figure 8A,B. Figure 8C,D shows OCT images of implants
filled with MB and IBU sodium and coated with H35L35P3.
Figure 6. Influence of (A) L-PCL and (B) PEG 1000 content on the contact angle of water with the polymeric films (means ± SD, n = 3).
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The materials (PLA, PVA, PCL, and PEG) used were chosen
because they are approved by the FDA and are biodegradable
(or soluble in the case of PVA).60 PLA is broken down by
hydrolysis of its ester backbone to form lactic acid, which can
be excreted.61 PVA is a water-soluble polymer which is
biocompatible and has excellent physical properties.62 PCL is
degraded to form products which are metabolized by the
tricarboxylic acid cycle or renally excreted.63 PCL has a
relatively long degradation time ranging from months to years,
although this is dependent on factors including molecular
weight and environmental conditions, such as temperature or
pH.50 PCL can easily form copolymers with other compounds,
for example PEG, to give it more favorable properties, such as
increased degradation rate.40,60
The architecture and topology of the implants and the
coatings were analyzed using a Bruker Skyscan 1172 system
μCT (Figure 8E−G). Cross section reconstructions in the y−z
plane of coated implants containing MB or IBU sodium were
performed, and representative x−y cross sections of implants
were used for quantitative analysis. These images provide an
appreciation of the drug distribution within the cavity of the
implant and the coating surrounding the implant. The
dimensional measurements calculated and different points on
the implant and implant coating are reported in Figure 8H and
show that there is no significant difference (p > 0.5) in the size
of the drug core for either model compound. These implants
were produced using an FFF printer. However, this type of
implant can be produced using alternative AM techniques.
Figure 7. Porosity of films made by solution casting of organic solutions of PCL and PEG 1000. (A) Percentage porosity of each of the films before
and after immersion in PBS (pH 7.4) for 60 days. (B) Percentage change in porosity of each of the films after immersion in PBS (pH 7.4) for 60
days. Pore size distribution curves of films measured at (C) 0 days and (D) 60 days in PBS (pH 7.4). (E) SEM images of an H35L35P30-coated
implant (1) before release and (2) after release. (F) Confocal microscope image of H35L35P30 film (before release) containing Nile red (shown in
red) and fluorescein (shown in green).
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Figure S2 (see Supporting Information) shows an example of
this type of implant prepared using a piston-based 3D printer.
This shows the versatility of the proposed design.
The thickness of the coating that was formed by each of the
films on the implants was measured (Figure 9A). Due to the
increased viscosity of the H100 and H50L50 solutions, they
formed significantly thicker (p < 0.01) coatings when
compared to the other formulations tested. A thicker coating
would have an effect on drug release from implants coated with
these formulations, as reported by Schlesinger et al.13 In that
study, the authors produced thin-film PCL devices containing
tenofovir alafenamide fumarate (TAF) with film thicknesses of
0.009, 0.015, and 0.026 mm. The devices demonstrated TAF
release rates of 4.4, 2.2, and 1.6 mg/day, respectively.13
Therefore, the concentration of the coating solution was
altered to give coatings with no significant differences in
thickness (Figure 9B). The concentrations used were 200, 400,
500, and 500 mg/mL for H100, H50L50, H40L60, and
H35L35P30, respectively.
3.4. In Vitro Release. Release of both MB and IBU sodium
from uncoated implants was rapid, and 100% drug release was
achieved in 7 days and 80 min for MB and IBU sodium,
respectively.23 The differences in release rate are most likely
due to differences in the solubilities and rates of solubilization
of the two compounds. MB and IBU sodium have solubilities
of 40 and 100 mg/mL, respectively.64,65
In order for the drug release to occur from the coated
implants, water must first permeate through the film coating to
dissolve the PVA “window” and solubilize the drug core.
Subsequently, dissolved drug can permeate through the film
Figure 8. Images of (A) an implant filled with MB and (B) an implant filled with IBU sodium. OCT images of (C) an implant filled with MB and
(D) an implant filled with IBU sodium. MicroCT images of (E) a representative x−y cross section of an implant used for quantitative analysis and
cross section reconstructions in the y−z plane of implants containing (F) MB and (G) IBU sodium. (H) Dimensional measurements calculated at
different locations over the implant 3D volume for the core, shell, and coating of the samples reported in (F) and G).
Figure 9. Thicknesses of each of the implant coatings (A) before correction and (B) after thickness correction (means ± SD, n = 4) ***P < 0.0001,
**P < 0.01, and ns = no significant difference.
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and be released into the surrounding media. As expected, the
release profiles from the coated implants (Figure 10A,B) are
substantially extended when compared to those of the
uncoated equivalents.23 As expected, H40L60 and
H35L35P30 showed the most rapid release profiles, likely
because these formulations contained the lowest proportion of
H-PCL and H35L35P30 also contained PEG 1000, which can
form hydrophilic pores, as seen in Figure 7F. As a result, these
films have an increased hydrophilicity, which will increase
water penetration,53 resulting in an increase in the rate of
degradation of these membranes and, therefore, an increased
rate of drug release.63,66 As expected, the release profile from
the implant coated in H100 was the slowest. This was expected
due to the slow degradation of this formulation and reduced
pore formation described in previous sections. Implants coated
in H50L50 showed a promising release profile for a prolonged
drug delivery system.
Similarity and difference factor are statistical tools normally
used to compare the dissolution profiles of oral solid dosage
forms.67 However, they have been successfully used before to
compare drug release from different types of formulations such
as transdermal patches,68−71 implants,72 and long-acting
injections.73 All release profiles were found to be different
from each other, as the calculated F1 was more than 15 and F2
was less than 50 for each case (Table 2). This emphasizes the
effect that changing the formulation has on the release profile
from the implant. Release rates of each of the release profiles
during their linear phases were calculated (Table 3).
Subsequently, these release rates were compared. Significant
differences (p < 0.05) were observed between all formulations
except between H40L60 and H35L35P30 (p > 0.05). These
results suggest that the release rates of the linear parts of these
two curves are equivalent. However, F1 and F2 are used to
compare the entire release profile. In this way it can be
concluded that H40L60 and H35L35P30 showed equivalent
release rates during the linear sections of the curves, but the
overall release curves are different whenever they deviate from
linearity.
Release experiments were conducted with IBU sodium to
allow the effect of drug properties on the release from these
coated implants to be investigated (Figure 11). Similar trends
were observed for MB and IBU sodium. All coated IBU
sodium implants showed more extended release when
compared to the uncoated implant.23 H40L60 showed the
most rapid release rate, followed by H35L35P30 and H50L50,
and H100 showed the slowest release rate. Although similar
trends are observed for the release rates for all formulations, it
is important to note that IBU sodium release was considerably
Figure 10. In vitro release profiles of MB-coated implants: (A) release from 0−50 days and (B) release from H100 and H50L50 continued to 160
days (means ± SD, n = 3).
Table 2. Difference (F1) and Similarity (F2) Factors of Each
Release Profile for MB Release from the Coated Implant
Design
curve 1 curve 2 F1 F2
H100 H50L50 97.60 33.24
H50L50 H40L60 84.09 18.60
H50L50 H35L30P30 89.46 16.20
H40L60 H35L35P30 16.82 49.29
Table 3. Release Rate of MB from Each of the Implant
Designs (Means ± SD, n = 3)
implant coating release rate (mg/day)
H100 0.01 ± 0.01
H50L50 0.27 ± 0.02
H40L60 1.52 ± 0.10
H35L35P30 1.60 ± 0.12
Figure 11. In vitro release profile of IBU sodium from coated implants
(means ± SD, n = 3).
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faster than MB release from the same coated implant. This
increase in release rate for IBU sodium may be attributable to
both the solubility of the drug and the dissolution rate of the
drug. Therefore, drug properties will have a significant effect
on the release profile from these implants, and this highlights
the difficulties in prolonging the drug release of highly
hydrophilic compounds. Interestingly, when IBU is loaded,
the implants coated with H40L60 showed faster drug release
than implants coated with H35L35P30. This behavior was not
observed in the release of MB. This fact reinforces the
conclusion that the permeation of drugs through these PCL-
based membranes relies heavily on the nature of the drug.
The release profiles of the coated implants were compared
using F1 and F2, and all release profiles were found to be
different (Table 4). These results suggest that all release
profiles were different from each other, as in all cases the
calculated F1 was more than 15 and F2 was less than 50.
Release rates of each of the release profiles (Table 5) were
compared, and significant differences (p < 0.05) were observed
between all formulations except H50L50 and H35L35P30 (p >
0.05). As explained before, this takes into account only the
release rates of the linear regions and not the release plot. It
can be clearly seen in Figure 11 that the release profiles of
these two types of implants are different. Moreover, this was
confirmed after calculating the similarity and difference factors
(F1 and F2).
This work demonstrates the impact that both implant design
and drug properties have on the release profile from an
implantable drug delivery device. Table 4 summarizes the
release rate from each of the implants investigated in this work.
Release rates ranging from 0.01 to 34.09 mg/day were
achieved as a result of changing the coating formulation and
the differing properties of the drug within the implant. No
significant difference (p > 0.05) between the release rates of
MB and IBU sodium from H100 implants were observed;
however, significant differences (p < 0.05) for all other
formulations were observed. These results emphasize the
difficulties in sustaining the release of hydrophilic drugs. IBU
sodium is more hydrophilic than MB and, as such, has
additional challenges to extending its release profile. The work
in this paper is a proof of concept using model drugs; however,
the implant coating could be modified for specific drugs, or
additionally extra excipients could be added to the powder
drug core to influence the rate of release.
There are many conditions that this type of implant may be
suitable for. For example, an implant coated with H35L35P30
could be suitable for pre-exposure prophylaxis (PrEP) of HIV
using TAF, as it is estimated that a dose of less than 2.8 mg/
day could be effective for this purpose, if delivered
subcutaneously.13 This work focuses on prolonging the
delivery of hydrophilic molecules, such as ropinirole
(maximum daily dose of 4 mg for restless leg syndrome74)
or local delivery of gentamicin after surgery. However, similar
implants could be designed for potent hydrophobic drugs and
conditions including risperidone for chronic psychosis (daily
dose 4 mg75) or levothyroxine for hypothyroidism (daily dose
100−200 μg76). However, further work needs to be conducted
to specifically design an implant for each release rate required.
The flexibility of the manufacturing techniques used in this
work may also allow for the design of complex implantable
devices which could deliver multiple drugs at differing rates, as
is the case for combinations of hormonal contraceptives:77
ethinylestradiol (20−35 μg/day), levonorgestrel (150 μg/day),
and gestodene (75 μg/day), among others.
4. CONCLUSION
In this work, hollow implants with dimensions similar to those
already available on the market were successfully produced
using AM. Subsequently, the implants were coated with a
degradable polymeric film coating to control drug release.
Eight film formulations were made from H-PCL, L-PCL, and
PEG 1000 and characterized using a variety of techniques
including DSC, porosity, μ-CT, and OCT, among others. The
most promising formulations underwent in vitro release testing
using two model compounds. Release rates ranging from 0.01
to 34.09 mg/day were obtained and could be easily modified
by changing the formulation of the polymeric coating. The
results presented in this work demonstrate the flexibility of the
implants produced and highlight their potential for sustaining
the release of hydrophilic compounds. However, the
manufacturing methods do not limit the applications to
hydrophilic drugs, and the implant could be tailored to the
properties of any drug compound. The present work was a
proof-of-concept study, and future work will aim to develop an
implant with a specific release rate for a drug and condition.
Additionally, as AM is still a relatively new technique in the
pharmaceutical industry, approaches to scale up this method of
manufacture need to be investigated.
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O’Donnell, K.; Larrañeta, E.; Lamprou, D. A. Fused deposition
modeling as an effective tool for anti-infective dialysis catheter
fabrication. ACS Biomater. Sci. Eng. 2019, 5, 6300−6310.
Molecular Pharmaceutics pubs.acs.org/molecularpharmaceutics Article
https://dx.doi.org/10.1021/acs.molpharmaceut.0c00515
Mol. Pharmaceutics XXXX, XXX, XXX−XXX
L
(27) Domínguez-Robles, J.; Mancinelli, C.; Mancuso, E.; García-
Romero, I.; Gilmore, B. F.; Casettari, L.; Larrañeta, E.; Lamprou, D.
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(71) Larrañeta, E.; Lutton, R. E. M.; Brady, A. J.; Vicente-Peŕez, E.
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